Boston Scientific Closes Neovasc Transaction

December 13, 2016—Boston Scientific Corporation announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc. advanced biological tissue business. With the completion of the acquisition, Boston Scientific will integrate certain manufacturing assets and biologic tissue capabilities into its structural heart business for use in the manufacturing of the Lotus valve system and future heart valve technologies. On December 2, the two companies announced a definitive agreement for Boston Scientific to acquire the advanced biologic tissue capabilities and make a 15% equity investment in Neovasc, for a total of $75 million in cash.